Short Interest in Lantern Pharma Inc. (NASDAQ:LTRN) Rises By 40.0%


Share on StockTwits

Lantern Pharma Inc. (NASDAQ:LTRN) was the target of a large increase in short interest in March. As of March 31st, there was short interest totalling 228,000 shares, an increase of 40.0% from the March 15th total of 162,900 shares. Based on an average daily trading volume, of 228,000 shares, the short-interest ratio is presently 1.0 days. Approximately 3.0% of the shares of the stock are short sold.

A number of hedge funds have recently added to or reduced their stakes in LTRN. BlackRock Inc. bought a new stake in shares of Lantern Pharma in the 3rd quarter worth approximately $94,000. Morgan Stanley bought a new stake in shares of Lantern Pharma in the 3rd quarter worth approximately $403,000. CM Management LLC bought a new stake in shares of Lantern Pharma in the 4th quarter worth approximately $193,000. Finally, Wolff Wiese Magana LLC bought a new stake in shares of Lantern Pharma in the 1st quarter worth approximately $491,000. 2.58% of the stock is owned by institutional investors and hedge funds.

LTRN stock traded up $0.13 during midday trading on Monday, reaching $15.59. The company had a trading volume of 332 shares, compared to its average volume of 211,365. The company has a debt-to-equity ratio of 0.01, a current ratio of 27.58 and a quick ratio of 27.58. Lantern Pharma has a 1 year low of $10.40 and a 1 year high of $24.84. The firm has a 50-day moving average price of $18.21 and a 200-day moving average price of $17.53.

Lantern Pharma (NASDAQ:LTRN) last released its quarterly earnings results on Wednesday, March 10th. The company reported ($0.47) EPS for the quarter, hitting the Zacks’ consensus estimate of ($0.47). On average, analysts predict that Lantern Pharma will post -1.25 EPS for the current fiscal year.

Lantern Pharma Company Profile

Lantern Pharma Inc, a clinical stage oncology biotechnology company, focuses on the development of precision oncology therapeutics using artificial intelligence, genomics, and machine learning. Its advanced drug candidate is LP-100, which is in phase II clinical trials to treat metastatic, castration-resistant, prostate cancer.

Featured Story: Learning About the VIX – Volatility Index

Receive News & Ratings for Lantern Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lantern Pharma and related companies with MarketBeat.com's FREE daily email newsletter.